| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by har..
>Volltext.. |
| 8385.5 Mio. EUR |
| 7841.44 Mio. EUR |
| - |
| - |
| - |
| - |
| 45.62 Mio. EUR |
| 586.25 Mio. EUR |
| - |
| 7.49 |
| - |
| - |
| - |
| - |
| - |
| - |
| ABIVAX |
| 28.02.26 |
|
||||
|